Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:ANIP NASDAQ:BMRN NASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$16.52-1.4%$18.63$13.50▼$25.67$4.00B0.383.14 million shs4.19 million shsANIPANI Pharmaceuticals$81.48+18.1%$65.19$52.50▼$83.80$1.49B0.61367,440 shs2.10 million shsBMRNBioMarin Pharmaceutical$57.33-3.6%$57.29$52.93▼$94.85$11.42B0.182.31 million shs3.52 million shsLGNDLigand Pharmaceuticals$150.06+2.6%$122.22$93.58▼$151.55$2.82B0.85207,614 shs195,533 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-9.65%-10.43%-5.95%-16.21%+46.29%ANIPANI Pharmaceuticals-0.12%+8.93%+6.06%+4.12%+21.05%BMRNBioMarin Pharmaceutical-1.99%+2.78%+2.53%+1.02%-31.10%LGNDLigand Pharmaceuticals+2.75%+11.20%+27.10%+40.05%+56.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics4.2927 of 5 stars3.73.00.00.03.62.53.1ANIPANI Pharmaceuticals3.2094 of 5 stars1.51.00.03.33.23.31.3BMRNBioMarin Pharmaceutical4.9933 of 5 stars4.45.00.03.33.92.54.4LGNDLigand Pharmaceuticals3.6483 of 5 stars1.51.00.04.43.13.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6767.47% UpsideANIPANI Pharmaceuticals 3.00Buy$83.252.17% UpsideBMRNBioMarin Pharmaceutical 2.75Moderate Buy$93.1762.52% UpsideLGNDLigand Pharmaceuticals 3.00Buy$157.004.62% UpsideCurrent Analyst Ratings BreakdownLatest LGND, ADMA, ANIP, and BMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$84.00 ➝ $93.008/8/2025ANIPANI PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$94.008/8/2025LGNDLigand PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$155.00 ➝ $185.008/6/2025BMRNBioMarin PharmaceuticalGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$101.00 ➝ $106.008/5/2025BMRNBioMarin PharmaceuticalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$94.008/5/2025BMRNBioMarin PharmaceuticalUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$113.00 ➝ $114.007/30/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$145.00 ➝ $162.007/22/2025BMRNBioMarin PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$97.00 ➝ $96.007/15/2025BMRNBioMarin PharmaceuticalWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$95.007/14/2025BMRNBioMarin PharmaceuticalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$108.00 ➝ $113.007/10/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$84.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M9.25$0.53 per share30.95$1.67 per share9.89ANIPANI Pharmaceuticals$614.38M2.87$8.97 per share9.08$19.11 per share4.26BMRNBioMarin Pharmaceutical$2.85B3.86$3.13 per share18.32$31.39 per share1.83LGNDLigand Pharmaceuticals$167.13M17.32$1.65 per share91.06$42.94 per share3.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8519.2123.94N/A44.06%41.01%28.47%N/AANIPANI Pharmaceuticals-$18.52M-$1.27N/A19.35N/A-3.12%21.35%7.52%8/8/2025 (Estimated)BMRNBioMarin Pharmaceutical$426.86M$3.3717.0113.150.8221.45%12.59%10.13%N/ALGNDLigand Pharmaceuticals-$4.03M-$7.12N/A40.45N/A-40.44%-9.21%-8.09%N/ALatest LGND, ADMA, ANIP, and BMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025ANIPANI Pharmaceuticals$1.42$1.80+$0.38$0.36$187.18 million$211.37 million8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54$1.60+$0.06$0.24$43.87 million$47.63 million8/6/2025Q2 2025ADMAADMA Biologics$0.14$0.15+$0.01$0.14$121.77 million$121.98 million5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/ABMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.215.333.36ANIPANI Pharmaceuticals1.462.661.98BMRNBioMarin Pharmaceutical0.105.563.49LGNDLigand PharmaceuticalsN/A5.455.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%ANIPANI Pharmaceuticals76.05%BMRNBioMarin Pharmaceutical98.71%LGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.50%ANIPANI Pharmaceuticals11.10%BMRNBioMarin Pharmaceutical0.85%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million230.38 millionOptionableANIPANI Pharmaceuticals60021.66 million19.26 millionOptionableBMRNBioMarin Pharmaceutical3,040192.01 million190.15 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.94 millionOptionableLGND, ADMA, ANIP, and BMRN HeadlinesRecent News About These CompaniesLigand Pharmaceuticals (NASDAQ:LGND) Updates FY 2025 Earnings Guidance4 hours ago | marketbeat.comLigand Pharmaceuticals Inc (LGND) Q2 2025 Earnings Call Highlights: Robust Royalty Growth and ...August 8 at 2:12 AM | gurufocus.comLigand Pharmaceuticals Incorporated 2025 Q2 - Results - Earnings Call PresentationAugust 7 at 8:01 PM | seekingalpha.comLigand Pharmaceuticals (NASDAQ:LGND) Sets New 12-Month High - Still a Buy?August 7 at 4:43 PM | marketbeat.comLigand Pharmaceuticals Q2 2025 Earnings: Revenue Surpasses Estimates at $47. ...August 7 at 7:49 AM | gurufocus.comLigand Reports Second Quarter 2025 Financial Results and Raises GuidanceAugust 7 at 7:00 AM | globenewswire.comJohn W. Kozarich Sells 467 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockAugust 6 at 8:24 PM | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Director John W. Kozarich Sells 467 SharesAugust 6 at 6:14 AM | insidertrades.comLigand Pharmaceuticals (LGND) to Release Earnings on ThursdayAugust 5 at 2:15 AM | americanbankingnews.com2,519 Shares in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Bought by Pacer Advisors Inc.August 2, 2025 | marketbeat.comOppenheimer Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) StockJuly 31, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Invests $2.22 Million in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 31, 2025 | marketbeat.comLigand Pharmaceuticals (LGND) Expected to Announce Quarterly Earnings on ThursdayJuly 31, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of "Buy" by AnalystsJuly 30, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Holdings Decreased by Essex Investment Management Co. LLCJuly 29, 2025 | marketbeat.comVictory Capital Management Inc. Has $2.91 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 29, 2025 | marketbeat.comEnvestnet Asset Management Inc. Sells 60,587 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 28, 2025 | marketbeat.comLigand Pharmaceuticals Inc (LGND) Announces Upcoming Q2 2025 Financial Results Release | LGND ...July 24, 2025 | gurufocus.comLigand to Report Second Quarter 2025 Financial Results on August 7, 2025July 24, 2025 | globenewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Sets New 52-Week High - Time to Buy?July 22, 2025 | marketbeat.comBank of New York Mellon Corp Sells 3,421 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLGND, ADMA, ANIP, and BMRN Company DescriptionsADMA Biologics NASDAQ:ADMA$16.52 -0.23 (-1.37%) Closing price 04:00 PM EasternExtended Trading$16.95 +0.43 (+2.61%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.ANI Pharmaceuticals NASDAQ:ANIP$81.48 +12.47 (+18.07%) Closing price 04:00 PM EasternExtended Trading$80.70 -0.78 (-0.95%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.BioMarin Pharmaceutical NASDAQ:BMRN$57.33 -2.13 (-3.58%) Closing price 04:00 PM EasternExtended Trading$57.86 +0.53 (+0.92%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Ligand Pharmaceuticals NASDAQ:LGND$150.06 +3.74 (+2.56%) Closing price 04:00 PM EasternExtended Trading$146.39 -3.67 (-2.45%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
